|
Akebia Therapeutics Inc (NASDAQ: AKBA) |
|
Akebia Therapeutics Inc
AKBA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Akebia Therapeutics Inc growth rates, revenue grew
by 75.84 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1683
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.49 %
Akebia Therapeutics Inc realized net income compared to net loss a year ago in first quarter of 2025
• More on AKBA's Growth
|
|
Akebia Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.83 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on AKBA's Valuation
|
|
|
|
|
Akebia Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.83 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
Akebia Therapeutics Inc Price to Book Ratio is at 25.65 lower than Industry Avg. of 33.04. and higher than S&P 500 Avg. of 0.01
• More on AKBA's Valuation
|
|
AKBA's Profitability Comparisons
|
Akebia Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 23.57 %.
Akebia Therapeutics Inc net profit margin of 10.66 % is currently ranking no. 32 in Major Pharmaceutical Preparations industry, ranking no. 73 in Healthcare sector and number 955 in S&P 500.
Profitability by Segment |
Total |
10.66 % |
|
|
Akebia Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 23.57 %.
Akebia Therapeutics Inc net profit margin of 10.66 % is currently ranking no. 32 in Major Pharmaceutical Preparations industry, ranking no. 73 in Healthcare sector and number 955 in S&P 500.
• More on AKBA's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com